SCHEMBL8467465

SCHEMBL8467465

N#CC1CN(Cc2ccccc2)CCN1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 3/20 0.49
SIGMAR1 Q99720 2/20 0.49
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MC4R P32245 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
KCNA3 P22001 1/20 0.42
TACR1 P25103 1/20 0.42
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
BACE1 P56817 1/20 0.41
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5426458 0.82 SIGMAR1 (0.52) DRD4SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL24027125 0.81 MC4R (0.51) DRD4SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL15709181 0.81 SIGMAR1 (0.55) DRD4SIGMAR1MC4RHTR1AKCNA3
SCHEMBL15575746 0.78 GCKR (0.41) DRD4SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL25154370 0.77 MAPK1 (0.66) DRD4SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL13699526 0.76 SIGMAR1 (0.52) DRD4SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL15315675 0.76 SIGMAR1 (0.52) DRD4SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL1773499 0.75 USP30 (0.49) ALDH1A1SMN1; SMN2
SCHEMBL27750453 0.75 SIGMAR1 (0.50) DRD4SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL9594552 0.75 SIGMAR1 (0.50) DRD4SIGMAR1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5922722-A PIPERIDINE OR PIPERAZINE DERIVATIVES TO TREAT BENIGN PROSTATIC HYPERPLASIA MERCK & CO., INC. (US) 1999-07-13 US disclosed
EP-0865280-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-09-23 EP disclosed
US-5807856-A Alpha 1a adrenergic receptor antagonist MERCK & CO., INC. (US) 1998-09-15 US disclosed
WO-1997017967-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-05-22 WO disclosed
WO-1997018209-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-05-22 WO disclosed
US-5223623-A 2-substituted-1(4)-aryl piperazines and the process for their preparation SCHERING AG (DE) 1993-06-29 US disclosed
EP-0491709-A1 2-SUBSTITUTED-1(4)-ARYL PIPERAZINES AND THE PROCESS FOR THEIR PREPARATION SCHERING AKTIENGESELLSCHAFT (DE) 1992-07-01 EP disclosed
US-5051422-A 2-substituted-1(4)-aryl piperazines and the process for their preparation SCHERING AG (DE) 1991-09-24 US disclosed
WO-1991004250-A1 2-SUBSTITUTED-1(4)-ARYL PIPERAZINES AND THE PROCESS FOR THEIR PREPARATION SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1991-04-04 WO disclosed